Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.

@article{Herscher1998PhaseIS,
  title={Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.},
  author={Laurie L. Herscher and Stephen M. Hahn and Glenn Kroog and Harvey I. Pass and Barbara K. Temeck and Barry R. Goldspiel and John T. Cook and James B. Mitchell and James E Liebmann},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1998},
  volume={16 2},
  pages={635-41}
}
PURPOSE To determine the maximum-tolerated dose (MTD) and dose-limiting toxicities of paclitaxel with concurrent thoracic irradiation in patients with malignant pleural mesothelioma and locally advanced non-small-cell lung cancer (NSCLC) using a 120-hour continuous infusion regimen. A secondary objective was to assess the effect of paclitaxel on the cell cycle through serial tumor biopsies. PATIENTS AND METHODS Paclitaxel was administered as a 120-hour (5-day) continuous infusion repeated… CONTINUE READING

Similar Papers

Loading similar papers…